pharmaphorum1d
Boehringer drug for brain fog in schizophrenia fails trial
As a result of the disappointing results, Boehringer said that it was abandoning a long-term extension trial called CONNEX-X, ...
Medscape1d
Novel Therapy Linked to Cognitive Benefit in Schizophrenia
Xanomeline/trospium chloride may help improve cognition in patients with acute schizophrenia and cognitive impairment, ...
Hosted on MSN2d
What Is the Difference Between Psychosis and Schizophrenia?
Medically reviewed by Dakari Quimby, PhD Psychosis and schizophrenia are related but distinct mental health conditions ...
Boehringer provides update on iclepertin Phase III program in schizophrenia
Boehringer Ingelheim today announced top-line results from the Phase III CONNEX clinical program in cognitive impairment in adults with ...
News Medical on MSN2d
Study reveals immune system changes linked to schizophrenia and treatment resistance
Researchers from Singapore's National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, ...
Monthly Prescribing Reference1d
Iclepertin Fails to Improve Cognitive Impairment in Schizophrenia Trial
The CONNEX program consisted of the randomized, double-blind, placebo-controlled phase 3 CONNEX-1, CONNEX-2, and CONNEX-3 studies ...
Pharmabiz1d
Boehringer Ingelheim’s phase III CONNEX clinical programme of iclepertin in schizophrenia fails to meet primary and key secondary endpoints
Ingelheim, Germany Saturday, January 18, 2025, 11:00 Hrs [IST] ...
FierceBiotech2d
Boehringer's phase 3 schizophrenia program misses primary goal
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...
National Elf Service5d
Alternatives to medication for ‘treatment-resistant schizophrenia’
Treatment-resistant schizophrenia (TRS) is generally understood as a failure to respond to at least two trials of ...